Table 1.
Descriptive Statistics of Analyzed Prostate Cancer Clinical Trials
| Trial Information | Treatment Trials (N=63) | Prevention Trials (N=4) | Screening Trials (N=5) | All Trials (N=72) |
|---|---|---|---|---|
| Earliest Recruitment Start Date | 1994 | 1993 | 1987 | 1987 |
| Latest Recruitment End Date | 2019 | 2012 | 2016 | 2019 |
| Availability of Race/Ethnicity Data, N (%): | ||||
| Trials with Available Race Data | 1 (81.0) | 4 (100) | 4 (80) | 59 (81.9) |
| Trials with Separate Ethnicity Data | 10 (15.9) | 1 (25) | 0 (0) | 11 (15.3) |
| U.S. Publicly Funded Trials | 9 (14.3) | 3 (75) | 1 (100)a | 13 (19.1)b |
| U.S. Non-Publicly Funded Trials | 54 (85.7) | 1 (25) | 0 (0) | 55 (80.9)b |
| Participant Information | Treatment Trials (N=38197) | Prevention Trials (N=62424) | Screening Trials (N=792757) | All Trials (N=893378) |
| Mean Number of Participants (SD) | 606 (538) | 15606 (14916) | 158551 (170776) | 12408 (57280) |
| Minimum Number of Participants | 10 | 423 | 9026 | 10 |
| Maximum Number of Participants | 1979 | 34888 | 419582 | 419582 |
| Availability of Race/Ethnicity Data, N (%): | ||||
| Participants with Available Race Data | 35014 (91.7) | 62424 (100) | 746564 (94.2) | 844002 (94.5) |
| Participants with Separate Ethnicity Data | 8091 (21.2) | 423 (0.7) | 0 (0) | 8514 (1.0) |
a
N=1 after exclusion of the four European/Canadian-only screening trials.
b
N=68 after exclusion of the four European/Canadian-only screening trials.